PROactive: Cutting Cardio Risk

Results from the landmark PROactive study were announced today at the 41st Annual Meeting of the European Association for the Study of Diabetes (EASD). Researchers found that the type 2 diabetes drug Actos (pioglitazone) "significantly reduces the combined risk of death, stroke, or heart attack by 16% in high-risk patients with type 2 diabetes who were already receiving optimised standard of care." PROactive is the first study to demonstrate that a glucose-lowering drug has a significant impact on lowering cardiovascular risk in type 2 patients.

Comments